Aclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjects

Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2011, Pages 923-932

  Lasseter, Kenneth C ^a   Aubets, Jordi ^b   Chuecos, Ferran ^b   Gil, Esther Garcia ^b  

^a Clinical Pharmacology of Miami   (United States)

^b NONE

Author keywords

Aclidinium bromide; biological availability; bronchodilators; cardiovascular safety; chronic obstructive pulmonary disease

Indexed keywords

ACLIDINIUM BROMIDE; GENUAIR; MOXIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR SYSTEM; CIRCADIAN RHYTHM; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HOLTER MONITORING; HUMAN; LABORATORY TEST; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PRURITUS; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINOLINES; TROPANES;

EID: 79955838243     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010374471     Document Type: Article

References (33)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006 ; 367: 1747-1757 (Pubitemid 43767064)
2. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006 ; 27: 397-412 (Pubitemid 43180921)
3. Maclay JD, McAllister DA, MacNee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007 ; 12: 634-641 (Pubitemid 47414891)
4. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008 ; 31: 204-212
5. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003 ; 107: 1514-1519 (Pubitemid 36378490)
6. Dahl MJ, Vestebo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 ; 175: 250-255 (Pubitemid 46203128)
7. Curkendall SM, Lanes S, de Luise C, et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol. 2006 ; 21: 803-813 (Pubitemid 44885203)
8. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007 ; 356: 775-789 (Pubitemid 46294610)
9. Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2004 ; 117 (suppl 12A). 24S - 32S
10. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest. 1996 ; 110: 62-70 (Pubitemid 26249303)
11. Disse B. Antimuscarinic treatment for lung diseases from research to clinical practice. Life Sci. 2001 ; 68: 2557-2564 (Pubitemid 32455694)
12. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci. 1993 ; 52: 521-527
13. Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Curr Opin Pharmacol. 2001 ; 1: 223-229 (Pubitemid 33585966)
14. Harvey RD, Belevych AE. Muscarinic regulation of cardiac ion channels. Br J Pharmacol. 2003 ; 139: 1074-1084 (Pubitemid 36920669)
15. Giachetti A, Micheletti R, Montagna E. Cardioselective profile of AF-DX 116, a muscarine M2 receptor antagonist. Life Sci. 1986 ; 38: 1663-1672 (Pubitemid 16072423)
16. Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther. 2009 ; 331: 740-751
17. Jansat JM, Lamarca R, Garcia Gil E, Ferrer P. Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. Int J Clin Pharmacol Ther. 2009 ; 47: 460-468
18. Jansat JM, Lamarca R, de Miquel G, Schrodter A, Miletzki B, Gurniak M. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol. 2009 ; 49: 1239-1246
19. Gras J, Gavaldà A, Llenas J. The preclinical cardiovascular safety profile of aclidinium bromide, a novel long-acting anticholinergic drug [abstract]. Am J Respir Crit Care Med. 2008 ; 177: A654
20. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville, Md: Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, US Department of Health and Human Services ; 2005 :
21. Peters RW, Gold MR. The influence of gender on arrhythmias. Cardiol Rev. 2004 ; 12: 97-105 (Pubitemid 38294873)
22. Bonnemeier H, Wiegand UK, Braasch W, Brandes A, Richardt G, Potratz J. Circadian profile of QT interval and QT interval variability in 172 healthy volunteers. Pacing Clin Electrophysiol. 2003 ; 26: 377-382 (Pubitemid 36399176)
23. Guidance for Industry: Bioanalytical Method Validation. Rockville, Md: Food and Drug Administration, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, US Department of Health and Human Services ; 2001 :
24. Malik MP, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002 ; 87: 220-228 (Pubitemid 34177674)
25. Pearson K. Contributions to the mathematical theory of evolution, II: skew variation in homogeneous material. Philos Trans R Soc Lond. 1895 ; 186: 343-414
26. Spearman C. The proof and measurement of association between two things. Am J Psychol. 1904 ; 15: 72-101
27. Holguin FE, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979-2001. Chest. 2005 ; 128: 2005-2011 (Pubitemid 41507534)
28. Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008 ; 84: 475-480
29. Malik MP, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol. 2004 ; 27: 1659-1669 (Pubitemid 40041518)
30. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008 ; 359: 1543-1554
31. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006 ; 130: 1695-1703 (Pubitemid 46033421)
32. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 ; 300: 1439-1450
33. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008 ; 149: 380-390